Gastroenterology
Volume 141, Issue 4 , Pages 1194-1201 , October 2011

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

  • Jean Frédéric Colombel

      Affiliations

    • Department of Hepatogastroenterology, CHU Lille and INSERM-CIC9301, Universite Lille Nord de France
    • Corresponding Author InformationReprint requests Address requests for reprints to: Jean Frédéric Colombel, MD, Hopital Claude Huriez, Centre Hopitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France 59037. fax: (33) 3-20-44-47-13
    • ,
  • Paul Rutgeerts

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Walter Reinisch

      Affiliations

    • Department of Gastroenterology and Hepatology, Universität Klinik für Innere Medizin III, AKH Wien, Vienna, Austria
    • ,
  • Dirk Esser

      Affiliations

    • Janssen Biologics, BV, Leiden, The Netherlands
    • ,
  • Yanxin Wang

      Affiliations

    • Schering Corporation, Subsidiary of Merck & Co, Inc, Kenilworth, New Jersey
    • ,
  • Yinghua Lang

      Affiliations

    • Department of Biostatistics, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, Pennsylvania
    • ,
  • Colleen W. Marano

      Affiliations

    • Department of Immunology, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, Pennsylvania
    • ,
  • Richard Strauss

      Affiliations

    • Department of Immunology, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, Pennsylvania
    • ,
  • Björn J. Oddens

      Affiliations

    • Schering Corporation, Subsidiary of Merck & Co, Inc, Kenilworth, New Jersey
    • ,
  • Brian G. Feagan

      Affiliations

    • Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
    • ,
  • Stephen B. Hanauer

      Affiliations

    • University of Chicago, Chicago, Illinois
    • ,
  • Gary R. Lichtenstein

      Affiliations

    • University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Daniel Present

      Affiliations

    • Mount Sinai Medical Center, New York, New York
    • ,
  • Bruce E. Sands

      Affiliations

    • Mount Sinai Medical Center, New York, New York
    • ,
  • William J. Sandborn

      Affiliations

    • University of California San Diego, La Jolla, California

Received 22 December 2010 ,Accepted 17 June 2011.

References 

  1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657
  2. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11–24
  3. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004;126:1582–1592
  4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845
  5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476
  6. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–1260
  7. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut. 1991;32:174–178
  8. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20
  9. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422
  10. Solberg IC, Lygren I, Jøhnsen J, et al. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut. 2008;57(Suppl 2):A-15
  11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis (A randomized study). N Engl J Med. 1987;317:1625–1629
  12. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782
  13. Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216–219
  14. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244–250
  15. Vatn MH. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis. 2009;27:470–475
  16. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433–442
  17. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–225
  18. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816
  19. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459
  20. Itzkowitz SH, Yio X. Inflammation and cancer IV (Colorectal cancer in inflammatory bowel disease: the role of inflammation). Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–G17
  21. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666

 Conflicts of interest Paul Rutgeerts, William Sandborn, Jean Frédéric Colombel, Stephen Hanauer, Gary Lichtenstein, Walter Reinisch, Bruce Sands, and Brian Feagan have served as consultants for Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC and Schering–Plough, a subsidiary of Merck & Co, Inc; Paul Rutgeerts, William Sandborn, Stephen Hanauer, Bruce Sands, Brian Feagan, Walter Reinisch, and Gary Lichtenstein have participated in continuing medical education events supported by unrestricted educational grants from Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC and Schering Corporation, a subsidiary of Merck & Co, Inc; Björn Oddens and Yanxin Wang are employees of Schering Corporation, a subsidiary of Merck & Co, Inc; Colleen Marano and Richard Strauss are employees of the Department of Immunology, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, and Yinghua Lang is an employee of the Department of Biostatistics, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC; and Dirk Esser is a former employee of Janssen Biologics BV and is currently an employee of Boerhringer–Ingelheim.

 Funding Supported by a research grant from Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC (Malvern, PA) and Schering Corporation, a subsidiary of Merck & Co, Inc (Kenilworth, NJ); this study was designed and conducted by the ACT-1 and ACT-2 Steering Committees, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC and Schering Corporation (a subsidiary of Merck & Co, Inc) who jointly analyzed and interpreted the data, and contributed to the manuscript; Drs Colombel, Rutgeerts, and Sandborn prepared the first draft of the manuscript, and the ACT-1 and ACT-2 Steering Committee made the decision to publish; editorial and writing support was provided by James P. Barrett, an employee of the Medical Affairs Publications Group, Janssen Services, LLC.

PII: S0016-5085(11)00904-8

doi: 10.1053/j.gastro.2011.06.054

Gastroenterology
Volume 141, Issue 4 , Pages 1194-1201 , October 2011

Article Tools

* Image Usage & Resolution